» Authors » Adhip Pn Majumdar

Adhip Pn Majumdar

Explore the profile of Adhip Pn Majumdar including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 8
Citations 277
Followers 0
Related Specialties
Top 10 Co-Authors
Published In
Affiliations
Soon will be listed here.
Recent Articles
1.
Farhana L, Antaki F, Murshed F, Mahmud H, Judd S, Nangia-Makker P, et al.
World J Gastrointest Pathophysiol . 2018 Oct; 9(2):47-58. PMID: 30283710
Aim: To determine whether and to what extent the gut microbiome is involved in regulating racial disparity in colorectal cancer (CRC). Methods: All patients were recruited and experiments were performed...
2.
Goyal S, Nangia-Makker P, Farhana L, Yu Y, Majumdar A
World J Stem Cells . 2016 Sep; 8(9):279-87. PMID: 27679684
Over the past two decades there has been remarkable progress in cancer diagnosis, treatment and screening. The basic mechanisms leading to pathogenesis of various types of cancers are also understood...
3.
Nangia-Makker P, Yu Y, Majumdar A
World J Gastrointest Pathophysiol . 2015 Nov; 6(4):86-9. PMID: 26600965
Colorectal cancer (CRC) that comprises about 50% of estimated gastrointestinal cancers remains a high mortality malignancy. It is estimated that CRC will result in 9% of all cancer related deaths....
4.
Levi E, Sochacki P, Khoury N, Patel B, Majumdar A
World J Gastrointest Pathophysiol . 2014 Aug; 5(3):366-72. PMID: 25133037
Aim: To demonstrated the combined effects of aging and carcinogen treatment on cancer stem/stem-like cells (CSCs) of gastric mucosa in an animal model. Methods: In this study we investigated the...
5.
Roy S, Majumdar A
J Mol Signal . 2012 Aug; 7(1):11. PMID: 22866952
: Colorectal cancer is the fourth most common form of cancer worldwide and ranks third among the cancer-related deaths in the US and other Western countries. It occurs with equal...
6.
Kanwar S, Poolla A, Majumdar A
World J Gastrointest Pathophysiol . 2012 Feb; 3(1):1-9. PMID: 22368781
Recurrence of colon cancer still remains a major issue which affects nearly 50% of patients treated by conventional therapeutics. Although the underlying causative factor(s) is not fully understood, development of...
7.
Nautiyal J, Kanwar S, Yu Y, Majumdar A
J Mol Signal . 2011 Jul; 6:7. PMID: 21774804
Metastatic colorectal cancer remains a serious health concern with poor patient survival. Although 5-Fluorouracil (5-FU) or 5-FU plus oxaliplatin (FOLFOX) is the standard therapy for colorectal cancer, it has met...
8.
Yu Y, Kanwar S, Patel B, Nautiyal J, Sarkar F, Majumdar A
Transl Oncol . 2009 Dec; 2(4):321-8. PMID: 19956394
5-Fluorouracil (5-FU) or 5-FU plus oxaliplatin (FOLFOX) remains the backbone of colorectal cancer chemotherapeutics but with limited success. This could partly be due to the enrichment of cancer stem cells...